Key Highlights
- Nine pharmaceutical companies have agreed to lower drug prices for Medicaid and cash-paying patients.
- The deal includes drugs for various conditions, including cancer, asthma, and diabetes.
- Fourteen companies in total have now entered into similar pricing agreements with the administration.
- The participating companies include Amgen, GSK, and Merck, among others.
- The initiative is part of efforts to address increasing health insurance premiums for Americans.
